Citadel Advisors LLC Takes Position in Hemab Therapeutics Holdings, Inc. $COAG

Citadel Advisors LLC bought a new position in shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 523,450 shares of the company’s stock, valued at approximately $19,226,000.

Separately, Braidwell LP purchased a new stake in Hemab Therapeutics in the 2nd quarter worth $5,877,000.

Hemab Therapeutics Stock Performance

Shares of NASDAQ COAG opened at $44.41 on Monday. The stock has a market cap of $2.07 billion and a PE ratio of -1.79. Hemab Therapeutics Holdings, Inc. has a 12-month low of $23.00 and a 12-month high of $55.42. The company’s 50-day simple moving average is $45.23.

Hemab Therapeutics (NASDAQ:COAG) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.17). On average, research analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -3.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Evercore initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 price objective on the stock. Jefferies Financial Group increased their target price on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a report on Monday, July 13th. The Goldman Sachs Group began coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 target price on the stock. Zacks Research raised Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Finally, Weiss Ratings assumed coverage on Hemab Therapeutics in a research report on Thursday, August 13th. They set a “sell (d+)” rating for the company. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Insider Activity at Hemab Therapeutics

In related news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was bought at an average cost of $24.98 per share, for a total transaction of $1,536,844.54. Following the acquisition, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Hemab Therapeutics Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.